Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Basel

Genomics England Research Summit 2025

This one-day, in-person event brings together Genomics England, its research community, and the broader genomic research and healthcare field to explore the latest advancements. Discover [...]

Go to Top